Objective: Objective and reproducible evaluation of data quality is of paramount importance for studies of 'real-world' observational data. Here, we summarise a standardised data quality, density and generalisability process implemented by MSBase, a global multiple sclerosis (MS) cohort study. Methods: Error rate, data density score and generalisability score were developed using all 35,869 patients enrolled in MSBase as of November 2015. The data density score was calculated across six domains (follow-up, demography, visits, MS relapses, paraclinical data and therapy) and emphasised data completeness. The error rate evaluated syntactic accuracy and consistency of data. The generalisability score evaluated believability of the demographic and treatment information. Correlations among the three scores and the number of patients per centre were evaluated. Results: Errors were identified at the median rate of 3 per 100 patient-years. The generalisability score indicated the samples' representativeness of the known MS epidemiology. Moderate correlation between the density and generalisability scores (ρ = 0.58) and a weak correlation between the error rate and the other two scores (ρ = −0.32 to −0.33) were observed. The generalisability score was strongly correlated with centre size (ρ = 0.79).
Introduction
Observational data play an important role in the multiple sclerosis (MS) research. While traditionally utilised in epidemiology and the research of risk factors, observational cohorts have become a valuable source of information for the studies of treatment effectiveness and safety, disease management and outcomes. 1 In particular, pragmatic trials utilising sophisticated analytical methodology, which have been known in diabetology and cardiology for more than two decades, 2,3 are now gaining momentum in neuroimmunology. [4] [5] [6] The evidence generated from observational data carries two important limitations: residual bias (for review, see Sormani and Bruzzi 7 ) and variable data quality. In MS research, the latter has yet to be addressed in a systematic way. The National Institutes of Health 8 has emphasised data quality and included it as a review criterion. A Data Quality Collaborative was established in order to address the problems with observational data quality and has published recommendations comprising descriptions of data capture, processing, data elements and analysis-specific data elements. 9 MSBase is a large, global observational cohort study, whose mission is to further the knowledge of MS epidemiology, aetiology and management and to generate evidence that will lead to improved outcomes of patients with this disease. 10 We have developed and implemented an automated data quality, density and generalisability process aiming at providing standardised, transparent, reproducible and highly granular information about the published data. The process will facilitate further improvement of data quality in MSBase and its collaborating centres. It will also enable quality-driven selection of research data and will enhance quality and generalisability of the generated evidence. Here, we provide a detailed overview of the MSBase data quality, density and generalisability process and demonstrate its translational potential.
Materials and methods

Ethics
MSBase (registered with WHO ICTRP, ID ACTRN12605000455662) was approved by the Melbourne Health Human Research Ethics Committee 10 and the local ethics committees in all participating centres (or exemptions were granted, according to local laws and regulations). Enrolled patients provided written informed consent as required.
Participants and definitions
The data quality and generalisability scores were developed using the information from all 35,869 patients diagnosed with MS or clinically isolated syndrome represented in MSBase as of November 2015. The prospective follow-up period was defined as the time between the first and last recorded disability scores. Disability was quantified by treating neurologists, using Expanded Disability Status Scale (EDSS). In order to minimise the EDSS inter-rater error, online Neurostatus certification was required at each participating centre (http://www.neurostatus.net). Relapses were defined as the occurrence of new symptoms, or exacerbation of existing symptoms, persisting for at least 24 hours, in the absence of concurrent illness or fever, and occurring at least 30 days after a previous relapse. 11 Confirmation by increased EDSS was not required.
Quality, density and generalisability of the recorded patient information were evaluated separately at each MSBase centre, assessing four quality metrics: 12 • • Completeness (the proportion of the critical variables with data not missing); • • Syntactic accuracy (the proportion of the recorded variables with the values corresponding to their range); • • Consistency (the proportion of variables congruent with other recorded variables); • • Believability (the proportion of entries which are regarded true and credible).
Data density score
Data density was assessed primarily with respect to completeness across six domains: cumulative followup, patient demography, clinical visits, MS relapses, paraclinical data and disease-modifying therapy ( Figure 1 ). The overall data density score was calculated as the sum of the scores within the six domains. The weights were chosen empirically in order to reflect the emphasis of the previous studies conducted using the MSBase data, that is, clinical descriptors of disease course and activity, and MS therapy.
Cumulative follow-up. Centres were awarded one point for every 1000 patient-years' worth of prospective clinical follow-up. To valorise the centres with patients followed prospectively from early after clinical disease onset, the proportion of patients with first EDSS visit recorded within the year following the Clinical visits. Density points were awarded for each visit recorded on average per patient, 1.3 points for the visits with recorded EDSS and 0.2 points for the visits with no EDSS available, which reflects the importance of the documented clinical information (administrative or phone visits were excluded).
Higher coefficient of variance of the annual visit frequency indicates greater variability in the frequency of clinical follow-up. Therefore, its inverse value was used as the score for regular clinical follow-up. year (0th or >85th centile)), based on the known epidemiology of MS relapses. 13 The completeness of the relapse-related information was evaluated as follows: the proportion of relapses with the information about the symptoms (maximum 3 points), severity (maximum 1.5 points), acute treatment (maximum 2 points), degree of recovery (maximum 1.5 points) and in addition up to 1 point for the proportion of relapses with all the above information recorded.
Paraclinical data. The paraclinical domain consisted of the information about brain magnetic resonance imaging (MRI) and cerebrospinal fluid: the mean annual frequency of MRI investigations (using square root transformation to mitigate its markedly skewed distribution), the proportions of MRIs with categorised information about contrast-enhancing lesions (maximum 4 points), new hyperintense T2 lesions (maximum 3 points), hyperintense T2 lesions (maximum 2 points), the proportion of patients with a recorded lumbar puncture (maximum 0.5 point), result of the cerebrospinal fluid analysis (maximum 1.5 points) and presence/ absence of IgG oligoclonal bands indicating intrathecal immunoglobulin synthesis (maximum 2 points).
Disease-modifying therapy. The therapy domain consisted of the score for the proportion of patients with ⩾5-year prospective follow-up after the diagnosis of clinically definite MS in whom disease-modifying therapy has been recorded (maximum 6 points when ⩾60% patients treated (⩾40th centile)), and the proportion of patients with adverse events recorded (maximum 3 points when ⩾2% (⩾40th centile)).
Error rate Data quality procedure assessed the recorded data at each centre for syntactic accuracy (i.e. the proportion of records which fall within the realistic range of the given variable) and consistency (i.e. counting incomplete or erroneous dates, dates of MS-related events inconsistent with the date of MS onset or birth date, contradictory entries, etc.). Data quality was evaluated across all six domains (see above) and quantified as the number of identified errors per 100 patientyears. In order to minimise inflation of its value, error rate was only calculated for centres with ⩾25 patientyears of cumulative follow-up.
Generalisability score
Generalisability score is indicative of data believability, which is defined as the proportion of entries that are regarded true and credible with respect to the known epidemiology of MS.
Information about demography and disease-modifying therapy was used to calculate the generalisability score separately at each MSBase centre. Female-tomale ratio was quantified with 6 (1.5-5.7:1), 3 (1-1.5:1 or 5.7-9:1) or 0 points (0-1:1 or >9:1). 14 The proportions of patients with the different MS phenotypes were evaluated as follows: relapsing-remitting MS, 4 points (60%-80%), 2 (15%-20% or 80%-90%) or 0 points (0%-50% or >90%); secondary progressive MS, 1 point (if 20%-35%, otherwise 0 points); and primary progressive MS, 0.5 points (if 7%-15%, otherwise 0 points). 15 The proportion of patients with ⩾5-year prospective follow-up after the diagnosis of clinically definite MS in whom any disease-modifying therapy has been recorded was scored with up to 4 points (when ⩾80% patients were treated). The proportion of the prospective follow-up time for which patients were treated with disease-modifying therapies was awarded up to 2.7 points (maximum at 90% of time, for more than 90% of the follow-up time, 2.4 points were awarded). For each disease-modifying therapy represented at MSBase centre (maximum 14 therapies), 0.4 points were awarded.
Data analysis
The scores were calculated and the analysis was performed using the R package (version 3.1.0). 16 The inferential statistics consisted of six tests of Spearman's rank correlation coefficients between the data error rate, data density score, generalisability score and the number of patients contributed to the MSBase cohort per centre.
Results
In November 2015, the MSBase cohort consisted of 35,869 patients, representing 179,594 patients-years and followed at 117 actively participating centres in 34 countries (see Supplementary Table 1 ). The median prospective follow-up was 3.4 years per patient, with the median interval between the visits with EDSS assessments being 8 months. The characteristics of the cohort are shown in Table 1 . Distributions of the variables that informed this assessment are shown in Table 2 . The list of individual variables used to calculate error rate and the density and generalisability scores for each centre is shown in Supplementary  Table 2 .
The error rate was calculated with the aim of quantifying syntactic accuracy and consistency of the information recorded by the MSBase centres. The median estimated error rate was 3 errors per 100 patient-years (interquartile range: 1.9-8.7). Centres contributing greater sample to the MSBase cohort tended to record lower error rates (ρ = −0.43, p = 10 -5 ; see Figure 2 ).
Completeness of the data was quantified using the data density score. Of its six domains, clinical visits and MS relapses contributed the largest weights to the overall score (31% and 26%, respectively). The data density score ranged from 1 to 103 points, with mean ± standard deviation of 36 ± 17. Similarly, the data density score was positively associated with the size of the MSBase centres (ρ = 0.37, p = 10 -5 ).
The purpose of the generalisability score was to quantify believability of the recorded information. We have estimated this as the representativeness of the patient cohort recorded at each of the MSBase centres with respect to the known epidemiology of MS and the use of disease-modifying therapies. The generalisability score consisted of the information concerning patient demography, MS phenotypes and exposure to disease-modifying therapy. It ranged from 0 to 21 points, with mean ± standard deviation of 14 ± 6 and was strongly correlated with MSBase centre size (ρ = 0.79, p < 10 -16 ).
The correlation of the error rate with the data density score (ρ = −0.32, p = 0.002) and the generalisability score (ρ = −0.33, p = 0.002) was only weak (Figure 3 ).
The data density score and the generalisability score were correlated with a moderate strength (ρ = 0.58, p = 10 -11 ).
Supplementary figure shows error rates and the generalisability scores and a break-down of the data density scores with its six domains for the individual MSBase centres. The majority of the centres reached error rates between 0 and 20 errors per 100 patient-years, with seven centres reaching error rates of <1. While for the majority of the centres the representation of the data density score components was proportional to the overall contribution of the components to the overall data density score, a small number of centres provided information from only a small number of patients and their scores were driven by the high granularity of the clinical visits data. These sub-cohorts typically represented treatment-specific cohorts with dense clinical follow-up (such as monthly EDSS in patients treated with natalizumab, which is a requisite of access to these therapies in some jurisdictions).
As an example of the implementation of the procedure aiming at maximising data quality, density and representativeness, we have applied the following criteria to model a patient sample from the MSBase cohort: maximum error rate of 1.6 per 100 patient-years, data density score ⩾60 (i.e. ⩾58% of the maximum score), generalisability score ⩾15 (i.e. ⩾71% of the maximum score) and number of patients contributed per centre ⩾25. . In 45% of women, a pregnancy was recorded. Of the selected patients, 70% have been exposed to disease-modifying therapies with the mean on-treatment time being 56% of the prospective follow-up; 13 disease-modifying therapies were represented. The recorded incidence of adverse events was 0.11 per patient-year. The mean frequency of brain MRI within the sample was 0.9 per year, with the entries containing the information about hyperintense T2 lesions, contrast-enhancing lesions, or the number of new T2 lesions in 45%, 41%, or 4%, respectively. In 63% of these patients, a lumbar puncture was recorded, with the information about the cytology and biochemistry recorded in 61% and oligoclonal bands in 27% of the patients. The average frequency of data entry errors was 1.1 per 100 patient-years.
Discussion
Using MSBase, a large global MS cohort study, we have developed and implemented a standardised data quality, density and generalisability process. The process quantifies completeness, accuracy, consistency and believability 12 of demographic, clinical and paraclinical information with respect to the specific requirements of an observational MS cohort. The resulting metrics enable monitoring and improvement of the quality of the data recorded at the participating centres and provide the basis for selecting highquality representative data for future analyses.
Hidden confounders represent a major limitation of the studies using observational cohorts. 1 These confounders often originate from the variability in the quality and density of the data recorded within multicentric observational datasets. The risk of hidden bias has prompted the development of recommendations for transparent reporting of data quality in distributed data networks. 9 MSBase in its multiple publications of observational data has previously used data quality procedures (see Online Supplement 2 for a typical MSBase data quality procedure). 17 However, there has been a need for a unified data quality, density and generalisability protocol, standardised across the MSBase centres, which would incorporate the recommendations of the Data Quality Collaborative, with the potential to inform similar procedures in other observational cohorts.
A methodological template for adopting the process quantifying data completeness, accuracy, consistency and believability was provided in the European Society of Thoracic Surgeons Database (in a setting of a cross-sectional registry). 18 We have extended this concept to a global longitudinal observational cohort study. In a multicentric registry, such evaluation then becomes suitable for comparison of data quality among the contributing sites, as demonstrated in the Manchester Orthopaedic Database. 19 Importantly, percentre evaluation of data quality enables identification of error (mainly systematic, and to a lesser extent also random) and provides an invaluable opportunity for improving data quality. An example of this was provided by the data quality process implemented by the Perfusion Downunder Collaboration, collecting information about cardiopulmonary bypass from three regional centres in South Australia. 20 Data quality and generalisability are closely related. For example, a Global Network's Maternal Newborn Health Registry (trial registration number NCT01073475) has implemented a performance metric in which data quality metrics (such as the proportion of enrolled subjects or the proportions of measured, estimated and missing birth weights) are combined with the generalisability metrics (such as gender ratio or ratio of stillbirths to early neonatal deaths) into a single composite score. 21 We have chosen to separate the error rate, and data density and generalisability scores in order to allow for a greater flexibility of their implementation. This allows us to take into consideration the purpose of data acquisition in the individual centres with respect to the scope of the MSBase studies (e.g. generalisability may be of a relatively greater importance for studies of MS epidemiology than studies of a therapeutic intervention in a specific subpopulation). 22 In fact, error rate was only weakly correlated with the data density and generalisability scores, and these are therefore likely to be complementary (for a more detailed discussion, see Kalincik and Butzkueven 1 ). The data density and generalisability scores were moderately correlated, which is partly determined by a modest overlap in the included variables (i.e. the proportion of patients treated with immunomodulatory therapies). The associations between centre size and error rate or the data density score were only weak, which confirms that the scores are not biased against the smaller centres. It is also worth noting that the data contributed by MSBase centres with relatively larger patient populations were more likely to be of relatively higher generalisability and therefore more representative of the general MS population.
The new standardised MSBase data quality process is comparable to the data quality assessment for drug safety surveillance system proposed by the Observational Medical Outcomes Partnership, with the emphasis on the detection of data anomalies (represented by the error rate) and determining their cause (as captured by the data density score). 23 Characterisation of the data source has been provided elsewhere. 10 Thus, the MSBase error rate and the density score address the issue of data plausibility and the generalisability score (together with the requirement of Neurostatus certification (http://www.neurostatus.net) for the purpose of disability evaluation at each active MSBase centre) partially addresses the issue of organisation. 24 However, in its present format, the MSBase data quality process does not involve source data verification and unified, global auditing. This is primarily restricted by the prohibitive cost of source data verification at the scale of a large international collaborative initiative. Hence, the actual data fidelity can only be expected in those MSBase centres where high plausibility and good organisation have been observed. 24 In addition, the limited scope of the audit trail implemented within the current MSBase data entry software (iMed) limits the ability to quantify the time lag between events and their entries. The above represent the opportunities for further improvement, namely establishing a unified auditing system and redeveloping the current MSBase audit trail. Because no normative base exists for longitudinal evaluation of MS data quality, on-going audit of the long-term impact of the data quality process is essential. Further areas for improvement are bundled with implementation of real-time congruence assessment within the MSBase data entry system.
The standardised data quality process described above will be implemented as an automated MSBase process. MSBase will periodically provide feedback to the participating centres including detailed characteristics of their contributed cohorts, their overall ranking in data quality, density and generalisability, as well as the ranking in each of the data density score domains.
The three scores will also be used to define cohorts above the minimum data quality, density and generalisability for inclusion in the future studies and, where applicable, to calculate weights used in statistical models. The flexibility allowed by the three separate scores and the six domains of the data density score will enable researchers to tailor these criteria with respect to the aims of the particular research studies.
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